HFA Premium Access

Safety, tolerability and discontinuation causes of sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.

Presentation

About the speaker

Doctor Marcelo Rizzo

Hospital Universitari Parc Tauli de Sabadell, Sabadell (Spain)
0 follower

56 more presentations in this session

Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Speaker: Doctor L. Buttigieg (Msida, MT)

Thumbnail

Sacubitril valsartan, a multicentric experience

Speaker: Mr F. Cortes (Seville, ES)

Thumbnail

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Speaker: Professor B. Kanazirev (Varna, BG)

Thumbnail

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Speaker: Doctor C. Hsu (Taipei, TW)

Thumbnail

Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy

Speaker: Doctor C. Hsieh (Taipei, TW)

Thumbnail

Access the full session

Poster Session 3 - Chronic Heart Failure – Treatment

Speakers: Doctor M. Rizzo, Doctor L. Buttigieg, Mr F. Cortes, Professor B. Kanazirev, Doctor C. Hsu...
Thumbnail

About the event

Image

Heart Failure 2019 - 6th World Congress on Acute Heart Failure

25 May - 28 May 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk